daclizumab + infliximab + sirolimus + tacrolimus

This is a combination immunosuppressive regimen consisting of four agents: - **Daclizumab** is a humanized monoclonal antibody targeting the interleukin-2 receptor alpha subunit (CD25) on activated T cells, thereby inhibiting IL-2 mediated activation and proliferation of lymphocytes. - **Infliximab** is a chimeric monoclonal antibody that binds to tumor necrosis factor-alpha (TNF-alpha), neutralizing its pro-inflammatory effects. - **Sirolimus** (also known as rapamycin) is an mTOR inhibitor that blocks signal transduction and clonal proliferation of lymphocytes by binding FKBP1A and inhibiting mTOR, thus preventing cell cycle progression in T and B cells. - **Tacrolimus** is a calcineurin inhibitor that suppresses T-cell activation by binding to FKBP12, forming a complex that inhibits calcineurin phosphatase activity, thereby blocking transcription of interleukin genes necessary for T-cell activation. This combination would provide broad-spectrum immunosuppression through multiple mechanisms affecting both cellular and humoral immune responses. While combinations such as sirolimus + tacrolimus or daclizumab + infliximab have been studied in transplantation or graft-versus-host disease settings[2][6][7], there are no reports describing the use of all four drugs together in clinical practice. Each drug has distinct toxicity profiles; combining them could increase the risk for over-immunosuppression and associated complications.